Ani Iabetic Drug Final
-
Upload
mitesh-shah -
Category
Documents
-
view
222 -
download
0
Transcript of Ani Iabetic Drug Final
-
8/9/2019 Ani Iabetic Drug Final
1/19
PRESENTATION ON PRODUCT
SURVEY OFANTI-DIABETIC AGENTS
Prepared By :Group 7
NiravHirenPunitKeyurMitesh
Bhupendra
-
8/9/2019 Ani Iabetic Drug Final
2/19
Introduction
Major Players
Product Range
Active Pharmaceutical Ingredient
Anti-diabetic Parental preparations Advertisement
Distribution Channel
Pricing
Conclusion
Reference
-
8/9/2019 Ani Iabetic Drug Final
3/19
Introduction
What is Diabetes ?
-Metabolic disorder-Characterized by chronic hyperglycemia
-
8/9/2019 Ani Iabetic Drug Final
4/19
Introduction
What is the purpose ofanti-diabetic agents?
Treat DiabetesManage Blood Sugar
-
8/9/2019 Ani Iabetic Drug Final
5/19
Major Players
Sa
lesgro
wth,2008
-09
(%)
Sales, 2009 ($bn)
Reference:- Business insights
-
8/9/2019 Ani Iabetic Drug Final
6/19
Major Players
Major
-ELLY LILLY
-NOVO NORDISK
-USV (us vitamin)
-SUN PHARMA
-TORRENT
-RANBAXY
-ZYDUS CADILA
-CADILA PHARMA
Others
-ALEMBIC
-SARABHAI
-INTAS
-OTSIRA GENETICA
-BAL PHARMA
-AVENTIS
-PANACEA
-DR. REDDYS LAB
-UNISEARCH
-FRANCO INDIAN
-MICRO LAD
-
8/9/2019 Ani Iabetic Drug Final
7/19
PRODUCT RANGE
Available in various dosage forms and in various quantity ofactive pharmaceutical ingredient.
- Control release tablets
- Sustain release tablets- Extended release tablets
- Semi tablets
- Capsules
- Parental preparation
(Subcutaneous rout of administration)
-
8/9/2019 Ani Iabetic Drug Final
8/19
Active Pharmaceutical Ingredient (API)
- Glibenclamide - Glipizide- Glicazide - Glimepride- Phenformin - Metformin
- Combination of Metformin and Glibenclamide- Combination of Metformin and Glipizide- Combination of Metformin and Gliclazide- Combination of Metformin and Glimepride
The quantity of API per tablet is also vary according to type of API and theavailable tablets contains following range of quantity
-0.5mg, 1mg, 1.25mg, 2mg, 3mg, 4mg, 5mg, 6mg, 8mg, 10mg, 15mg,30mg, 40mg, 50mg, 80mg, 100mg, 120mg, 125mg, 250mg, 850mg,
1000mg.
-
8/9/2019 Ani Iabetic Drug Final
9/19
Anti-diabetic Parental preparations
-Neutral Insulin (Soluble)
-Isophane Insulin (NPH)
-Insulin Zinc Suspension
-Premixed Biphasic Insulin
-Insulin Lispro
-Insulin Glargine
The major players in this market are ELI LILY and
NOVO NORDISK.
-
8/9/2019 Ani Iabetic Drug Final
10/19
ADVERTISEMENT OF ANTI-DIABETIC AGENTS
Medical representative
Magazine
Web site
Free sampling
Seminars
Brochure
Health check up camp and
counseling
Pharmaceutical fair - IPC
-
8/9/2019 Ani Iabetic Drug Final
11/19
DISTRIBUTION CHANNEL 1
-
8/9/2019 Ani Iabetic Drug Final
12/19
DISTRIBUTION CHANNEL 2
-
8/9/2019 Ani Iabetic Drug Final
13/19
Pricing
vLife saving drugs and under Drug Price Control Order
(DPCO)
v The margin on this kind of product is limited to 10 to
15%
-
8/9/2019 Ani Iabetic Drug Final
14/19
CONCLUSION
o Spreading globally
o Cross - 250 Million by end of 2010
o Injectable anti diabetic agents
o Oral anti diabetic agents
o Lower profitable margin
-
8/9/2019 Ani Iabetic Drug Final
15/19
Reference
1. William H. Herman, Ronald E. Aubert, Mohammad A. Ali, Edward
S. Sous andAhmed Badran. Diabetes mellitus in Egypt: risk factors, prevalenceand future burden. EMHJ Volume 3, Issue 1, 1997, Page 144-148.
2. Roberts AB, Baker JR, Metcalf P, et al. Fructosamine comparedwith a glucose load as a screening test for gestational diabetes.
Obstet Gynecol 1990;76:773-775.
3. Business insights
4. 12.17 Company Market Share (%) For Insulin Products for theEuropean Market.
5. Singer DE, Coley CM, Samet JH, et al. Tests of glycemia indiabetes mellitus. Ann Intern Med 1989;110:125-137.
-
8/9/2019 Ani Iabetic Drug Final
16/19
Thank
You
-
8/9/2019 Ani Iabetic Drug Final
17/19
-
8/9/2019 Ani Iabetic Drug Final
18/19
Introduction
-
8/9/2019 Ani Iabetic Drug Final
19/19
Elementswww.animationfactory.com